125 related articles for article (PubMed ID: 10932925)
1. [Treatment of hypertriglyceridemia. Current aspects].
Malaguarnera M; Giugno I; Ruello P; Vinci E; Panebianco MP; Motta M
Recenti Prog Med; 2000; 91(7-8):379-87. PubMed ID: 10932925
[TBL] [Abstract][Full Text] [Related]
2. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
3. Hypertriglyceridemia: management of atherogenic dyslipidemia.
Bersot T; Haffner S; Harris WS; Kellick KA; Morris CM
J Fam Pract; 2006 Jul; 55(7):S1-8. PubMed ID: 16822443
[TBL] [Abstract][Full Text] [Related]
4. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
5. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
6. A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Malloy MJ; Kane JP
Adv Intern Med; 2001; 47():111-36. PubMed ID: 11795072
[TBL] [Abstract][Full Text] [Related]
7. Management of hypertriglyceridemia.
Oh RC; Lanier JB
Am Fam Physician; 2007 May; 75(9):1365-71. PubMed ID: 17508532
[TBL] [Abstract][Full Text] [Related]
8. Management of hypercholesterolaemia in the patient with diabetes.
Packard C; Olsson AG
Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
[TBL] [Abstract][Full Text] [Related]
9. Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.
Plaisance EP; Grandjean PW; Mahurin AJ
Phys Sportsmed; 2009 Apr; 37(1):11-9. PubMed ID: 20048483
[TBL] [Abstract][Full Text] [Related]
10. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Hogue JC; Lamarche B; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Mar; 57(3):380-6. PubMed ID: 18249211
[TBL] [Abstract][Full Text] [Related]
12. Lipid management in the geriatric patient.
Nair AP; Darrow B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
[TBL] [Abstract][Full Text] [Related]
13. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
14. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
15. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Duvall WL; Blazing MA; Saxena S; Guyton JR
J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
17. What is the most effective strategy for managing diabetic dyslipidaemia?
Reasner CA
Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
[TBL] [Abstract][Full Text] [Related]
18. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
19. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
20. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
